RT Journal Article
T1 Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study.
A1 Vallejo Casas, Juan Antonio
A1 Sambo, Marcel
A1 Lopez Lopez, Carlos
A1 Duran-Poveda, Manuel
A1 Rodriguez-Villanueva Garcia, Julio
A1 Santos, Rita Joana
A1 Llanos, Marta
A1 Navarro-Gonzalez, Elena
A1 Aller, Javier
A1 Pubul, Virginia
A1 Guadalix, Sonsoles
A1 Crespo, Guillermo
A1 Gonzalez, Cintia
A1 Zafon, Carles
A1 Navarro, Miguel
A1 Santamaria-Sandi, Javier
A1 Segura, Angel
A1 Gajate, Pablo
A1 Gomez-Balaguer, Marcelino
A1 Valdivia, Javier
A1 Puig-Domingo, Manel
A1 Galofre, Juan Carlos
A1 Castelo, Beatriz
A1 Villanueva, Maria Jose
A1 Argüelles, Iñaki
A1 Orcajo-Rincon, Lorenzo
K1 Advanced differentiated thyroid cancer
K1 Epidemiological study
K1 Radioiodine-refractory differentiated thyroid cancer
K1 Relapsing differentiated thyroid cancer
K1 Relapsing prognostic factors
K1 Survival prognostic factors
AB Up to 30% of differentiated thyroid cancer (DTC) will develop advanced-stage disease (aDTC) with reduced overall survival (OS). The aim of this study is to characterize initial diagnosis of aDTC, its therapeutic management, and prognosis in Spain and Portugal. A multicentre, longitudinal, retrospective study of adult patients diagnosed with aDTC in the Iberian Peninsula was conducted between January 2007 and December 2012. Analyses of baseline characteristics and results of initial treatments, relapse- or progression-free survival ((RP)FS) from first DTC diagnosis, OS, and prognostic factors impacting the evolution of advanced disease were evaluated. Two hundred and thirteen patients (median age: 63 years; 57% female) were eligible from 23 hospitals. Advanced disease presented at first diagnosis (de novo aDTC) included 54% of patients, while 46% had relapsed from early disease (recurrent/progressive eDTC). At initial stage, most patients received surgery (98%) and/or radioiodine (RAI) (89%), with no differences seen between median OS (95% CI) (10.4 (7.3-15.3) years) and median disease-specific-survival (95% CI) (11.1 (8.7-16.2) years; log-rank test P = 0.4737). Age at diagnosis being  Identification of early treatment-dependent prognostic factors for an unfavourable course of advanced disease is possible. An intensified therapeutic attitude may reverse this trend and should be considered in poor-performing patients. Prospective studies are required to confirm these findings.
PB BioScientifica
SN 2235-0640
YR 2022
FD 2022-06-30
LK http://hdl.handle.net/10668/20449
UL http://hdl.handle.net/10668/20449
LA en
NO Vallejo Casas JA, Sambo M, López López C, Durán-Poveda M, Rodríguez-Villanueva García J, Santos RJ, et al. Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study. Eur Thyroid J. 2022 Aug 11;11(5):e210111
DS RISalud
RD Apr 10, 2025